Moreover, aberrant VDAC2 expression or functioning has been reported in multiple tumors, including melanoma, epithelial thyroid tumors, and breast cancer, indicating that targeting VDAC2 is of therapeutic significance for cancer treatment37–39. This evidence concerns the gene VDAC2 and melanoma.